Fig. 4

Patient enrollment and allocation in the validation cohort. AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis; CCL, C-C motif chemokine ligand; COP, cryptogenic organizing pneumonia; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; PPFE, pleuroparenchymal fibroelastosis